$CRVS

Corvus Pharmaceuticals reported their Q4 2025 earnings, highlighting a significant increase in revenue, which surpassed market expectations. The company announced promising data from its clinical trials, which could lead to potential FDA approval for its lead product. Additionally, Corvus indicated strategic partnerships that are expected to strengthen its market position. However, operational expenses also rose, impacting net income. Overall, the bullish outlook has generated optimism among investors despite some concerns over cost management.